多西他赛、表柔比星和环磷酰胺在乳腺癌新辅助化疗中的疗效观察

Curative effect observation of docetaxel,epirubicin and cyclophosphamide in new adjuvant chemotherapy of breascancer

目的:探讨多西他赛、表柔比星和环磷酰胺辅助化疗治疗乳腺癌的疗效。方法:收治乳腺浸润性导管癌患者139例,随机分为对照组71例和观察组68例,对照组给予TE方案(多西他赛+表柔比星)治疗,观察组给予TEC方案(多西他赛+表柔比星+环磷酰胺)治疗,比较两组的疗效。结果:观察组病理总有效率显著高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:乳腺癌患者新辅助化疗TEC方案病理有效率明显优于TE方案,且未增加不良反应。

Objective:To explore the curative effect of docetaxel,epirubicin and cyclophosphamide in new adjuvant chemotherapyof breast cancer.Methods:139 patients with breast infiltrating ductal carcinoma were selected.They were randomly divided into thecontrol group with 71 cases and the observation group with 68 cases.Patients in the control group were given the TEscheme(docetaxel plus epirubicin) for treatment,while patients in the observation group were given TEC scheme(docetaxel plusepirubicin plus cyclophosphamide) for treatment.We compared the effect of two groups.Results:In the observation group,the totaleffective rate of pathology was significantly higher than that in the control group(P<0.05).There was no significant difference inthe incidence of adverse reactions between groups(P>0.05).Conclusion:The effective rate of pathology of new adjuvantchemotherapy with TEC scheme for breast cancer was better than that of TE scheme,and it did not increase the adverse reaction.